| Literature DB >> 24273027 |
Cristina Aureli1, Tommaso Cassano, Alessandra Masci, Antonio Francioso, Sara Martire, Annalisa Cocciolo, Silvia Chichiarelli, Adele Romano, Silvana Gaetani, Patrizia Mancini, Mario Fontana, Maria d'Erme, Luciana Mosca.
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder whose etiology is still unclear in spite of extensive investigations. It has been hypothesized that 5-S-cysteinyldopamine (CysDA), a catechol-thioether metabolite of dopamine (DA), could be an endogenous parkinsonian neurotoxin. To gain further insight into its role in the neurodegenerative process, both CD1 mice and SH-SY5Y neuroblastoma cells were treated with CysDA, and the data were compared with those obtained by the use of 6-hydroxydopamine, a well-known parkinsonian mimetic. Intrastriatal injection of CysDA in CD1 mice caused a long-lasting depletion of DA, providing evidence of in vivo neurotoxicity of CysDA. Both in mice and in SH-SY5Y cells, CysDA treatment induced extensive oxidative stress, as evidenced by protein carbonylation and glutathione depletion, and affected the expression of two proteins, α-synuclein (α-Syn) and ERp57, whose levels are modulated by oxidative insult. Real-time PCR experiments support these findings, indicating an upregulation of both ERp57 and α-Syn expression. α-Syn aggregation was also found to be modulated by CysDA treatment. The present work provides a solid background sustaining the hypothesis that CysDA is involved in parkinsonian neurodegeneration by inducing extensive oxidative stress and protein aggregation.Entities:
Keywords: 5-S-cysteinyldopamine; 6-hydroxydopamine; ERp57; Parkinson's disease; α-synuclein
Mesh:
Substances:
Year: 2013 PMID: 24273027 DOI: 10.1002/jnr.23318
Source DB: PubMed Journal: J Neurosci Res ISSN: 0360-4012 Impact factor: 4.164